SCHEMBL2700293

SCHEMBL2700293

CCOC(=O)c1c(NNC(=O)OC(C)(C)C)ncn1Cc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.51
CRHR2 Q13324 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.44
RECQL P46063 1/20 0.44
MAPK10 P53779 1/20 0.44
ADORA3 P0DMS8 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
GAA P10253 3/20 0.41
PKM P14618 1/20 0.41
TSHR P16473 1/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
F2RL3 Q96RI0 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2700156 0.80 SMN1; SMN2 (0.50) CRHBPCRHR2SMN1; SMN2RECQLMAPK10
SCHEMBL11213556 0.76 SMN1; SMN2 (0.55) CRHBPCRHR2SMN1; SMN2RECQLMAPK10
SCHEMBL1753091 0.74 SMN1; SMN2 (0.53) CRHBPCRHR2SMN1; SMN2RECQLMAPK10
SCHEMBL17456271 0.74 SMN1; SMN2 (0.53) CRHBPCRHR2SMN1; SMN2RECQLMAPK10
SCHEMBL7975190 0.71 NAMPT (0.46) KDM4EMAPT
SCHEMBL12429215 0.70 TP53 (0.49) SMN1; SMN2RECQLMAPK10GAAMEN1
SCHEMBL17456331 0.70 SMN1; SMN2 (0.48) CRHBPCRHR2SMN1; SMN2RECQLMAPK10
SCHEMBL7984483 0.69 TLR7 (0.43) ADORA3GAAPKMTSHRKDM4E
SCHEMBL27714659 0.69 MEN1 (0.47) ADORA3ADORA2AADORA1GAATSHR
SCHEMBL4958152 0.69 TSHR (0.54) SMN1; SMN2RECQLMAPK10GAAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194046-B1 Triazolone derivative EISAI R&D MAN CO LTD (JP) 2012-05-09 EP disclosed
US-7816522-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2010-10-19 US disclosed
US-7816522-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2010-10-19 US disclosed
US-7816522-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2010-10-19 US disclosed
EP-2194046-A1 Triazolone derivative Eisai R&D Management Co., Ltd. (JP) 2010-06-09 EP disclosed
EP-2000465-A1 TRIAZOLONE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2008-12-10 EP disclosed
US-20080015199-A1 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-01-17 US disclosed
US-20080015199-A1 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-01-17 US disclosed
US-20080015199-A1 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015199-A1 Triazolone derivatives F3, F12, F2 CRHBP 3626/4885CRHR2 1356/4885SMN1; SMN2 3935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.